Xeris Biopharma (NASDAQ:XERS) Insider Sells $99,835.33 in Stock

by · The Markets Daily

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $5.99, for a total value of $99,835.33. Following the completion of the transaction, the insider owned 1,209,840 shares in the company, valued at $7,246,941.60. This represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

  • On Monday, March 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.25, for a total transaction of $104,168.75.
  • On Monday, February 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.45, for a total value of $124,169.15.

Xeris Biopharma Price Performance

NASDAQ XERS remained flat at $6.04 during trading hours on Friday. The company’s stock had a trading volume of 1,338,751 shares, compared to its average volume of 1,911,411. The firm has a market cap of $1.04 billion, a P/E ratio of -603.40 and a beta of 0.77. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19. Xeris Biopharma Holdings, Inc. has a twelve month low of $3.81 and a twelve month high of $10.08. The firm has a 50-day moving average price of $6.36 and a 200 day moving average price of $7.30.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last issued its earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%.The business had revenue of $85.81 million during the quarter, compared to analyst estimates of $86.00 million. On average, sell-side analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds have recently modified their holdings of the company. Cetera Investment Advisers raised its stake in shares of Xeris Biopharma by 3.9% during the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock valued at $216,000 after acquiring an additional 1,735 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after purchasing an additional 1,820 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Xeris Biopharma by 7.6% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company’s stock valued at $150,000 after purchasing an additional 2,264 shares during the period. Royal Bank of Canada raised its position in Xeris Biopharma by 6.5% during the 4th quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock valued at $304,000 after purchasing an additional 2,351 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in Xeris Biopharma by 17.7% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,070 shares of the company’s stock valued at $126,000 after purchasing an additional 2,420 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Barclays assumed coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 price target for the company. Weiss Ratings raised Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a research note on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Xeris Biopharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

View Our Latest Analysis on Xeris Biopharma

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

Featured Stories